Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies.

چکیده

To evaluate the safety and efficacy of the transient receptor potential melastatin 8 agonist acoltremon on signs and symptoms of dry eye disease (DED). Two identical randomized, multicenter, double-masked, vehicle-controlled phase 3 studies. Adults aged 30 years or older with a DED diagnosis, at…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط